Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder. Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder.Magnific Wiskott-Aldrich syndrome is a rare inherited immune disorder affecting boys that causes eczema, immune deficiency, and bleeding. A new study shows that infusing gene-corrected stem cells provides lasting protection for patients. The FDA approved this therapy in December 2025 after citing a 93% drop in severe infections. Analysis of where the gene landed in the DNA showed blood production drawn from many different corrected cells, with no sign that the virus had disturbed cancer genes. The treatment still carries risks. Nineteen patients experienced serious adverse events. Most were infections. The study had no control group, which the authors note is inevitable in an ultra-rare disease. The FDA requires a · 15-year follow-up study to track secondary cancer risk. The path to approval is also unusual. The therapy began at an academic center, passed through pharmaceutical development and returned to Fondazione Telethon, an Italian nonprofit organization, which secured approval in Europe and the U.S. The FDA describes it as the first cell and gene therapy approved by a nonprofit applicant. A durable treatment raises the stakes for early diagnosis. In this study, symptoms started at a median age of about four months, and diagnosis followed at a median age of one year. Genetic testing of mothers in affected families, and · genome sequencing at birth, can identify boys with the disease before the first serious infection. The lesson of this study reaches beyond one rare disease.